Elite Pharmaceuticals and Cumberland Pharmaceuticals follow different growth paths, but which looks more compelling now? Let's dive in.
ELTP delivers record fiscal 2026 results, with stronger profits, improved cash and pipeline progress supporting its expanding generics platform.
Elite Pharmaceuticals, Inc. (ELTP) Q4 2026 Earnings Call Transcript
ELTP reports surging revenue and profit in third-quarter fiscal 2026, but margin pressure and M&A ambitions steal the spotlight.
Elite Pharmaceuticals delivers record second-quarter fiscal 2026 earnings as lisdexamfetamine sales surged, though margins faced competitive pressure.
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q2 2026 Earnings Call November 17, 2025 11:30 AM EST Company Participants Nasrat Hakim - Chairman, CEO & President Carter Ward - CFO, Secretary & Treasurer Presentation Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Second Quarter of Fiscal Year 2026 Conference Call. [Operator Instructions] Before management begins speaking, the conference has the following statement.
Elite Pharmaceuticals reports strong first-quarter fiscal 2026 results with rising direct sales, higher-margin products and expanding gross profit.
ELTP and TSSI are growth stories with recent material pull-backs.
ELTP posts record fiscal 2025 revenues and operating income gains, fueled by new launches and expanding generics market share.
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q4 2025 Earnings Conference Call July 1, 2025 11:30 AM ET Company Participants Carter J. Ward - CFO, Secretary & Treasurer Nasrat Hakim - Chairman, CEO & President Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Conference Call.
Elite Pharmaceuticals' third-quarter fiscal 2025 reports a revenue drop and a net loss. However, delayed shipments impact results.
Here we highlight a small cap and a microcap with Zacks Outperform ratings.